Indivior

Court Provides Final Approval of Settlement with Direct Purchaser Class in the Multidistrict Antitrust Litigation; Final Court Approval Concludes the Antitrust Multidistrict Litigation

Retrieved on: 
Thursday, February 29, 2024

RICHMOND, Va., Feb. 29, 2024 /PRNewswire/ -- Indivior PLC (LSE: INDV; Nasdaq: INDV), a leading addiction treatment company, today announced that its subsidiary, Indivior Inc., has received final Court approval for its settlement with the Direct Purchaser class, concluding the anti-trust multi-district litigation ("MDL") matter.

Key Points: 
  • RICHMOND, Va., Feb. 29, 2024 /PRNewswire/ -- Indivior PLC (LSE: INDV; Nasdaq: INDV), a leading addiction treatment company, today announced that its subsidiary, Indivior Inc., has received final Court approval for its settlement with the Direct Purchaser class, concluding the anti-trust multi-district litigation ("MDL") matter.
  • On October 22, 2023, Indivior Inc. entered into a settlement agreement with the remaining Direct Purchaser class for $385m.
  • On February 27, 2024, the United States District Court for the Eastern District of Pennsylvania entered an order granting final judgement and order of dismissal approving the Direct Purchaser class settlement and dismissing the Direct Purchaser class claims.
  • This ruling concludes the Antitrust MDL.

Indivior Announces Q4 / FY 2023 Financial Results

Retrieved on: 
Thursday, February 22, 2024

SLOUGH, United Kingdom and RICHMOND, Va., Feb. 22, 2024 /PRNewswire/ -- Indivior PLC (LSE/Nasdaq: INDV) today announced its financial results for the period ending December 31, 2023.

Key Points: 
  • SLOUGH, United Kingdom and RICHMOND, Va., Feb. 22, 2024 /PRNewswire/ -- Indivior PLC (LSE/Nasdaq: INDV) today announced its financial results for the period ending December 31, 2023.
  • The earnings release, investor presentation and webcast are available at www.indivior.com .
  • There will be a live webcast presentation at 13:00 BST (8:00 am EST) hosted by Mark Crossley, CEO.
  • Participants may access the presentation telephonically by registering with the following link: https://register.vevent.com/register/BI7bc18cb84a3744af8c4ad20973d37a5a

Indivior Announces Q4 / FY 2023 Financial Results

Retrieved on: 
Thursday, February 22, 2024

SLOUGH, United Kingdom and RICHMOND, Va., Feb. 22, 2024 /PRNewswire/ -- Indivior PLC (LSE/Nasdaq: INDV) today announced its financial results for the period ending December 31, 2023.

Key Points: 
  • SLOUGH, United Kingdom and RICHMOND, Va., Feb. 22, 2024 /PRNewswire/ -- Indivior PLC (LSE/Nasdaq: INDV) today announced its financial results for the period ending December 31, 2023.
  • The earnings release, investor presentation and webcast are available at www.indivior.com .
  • There will be a live webcast presentation at 13:00 BST (8:00 am EST) hosted by Mark Crossley, CEO.
  • Participants may access the presentation telephonically by registering with the following link: https://register.vevent.com/register/BI7bc18cb84a3744af8c4ad20973d37a5a

Calliditas announces additions to the management team

Retrieved on: 
Friday, December 1, 2023

STOCKHOLM, Dec. 1, 2023 /PRNewswire/ -- Calliditas Therapeutics AB (Nasdaq: CALT) (Nasdaq Stockholm: CALTX) ('Calliditas') today announced that the company has added a new member to its management team, Head of Technical Operations Lars Stubberud.

Key Points: 
  • STOCKHOLM, Dec. 1, 2023 /PRNewswire/ -- Calliditas Therapeutics AB (Nasdaq: CALT) (Nasdaq Stockholm: CALTX) ('Calliditas') today announced that the company has added a new member to its management team, Head of Technical Operations Lars Stubberud.
  • Brian Gorman is an accomplished legal and business executive with more than 20 years of experience advising corporate boards and executive management teams of life science companies.
  • He joins Calliditas after having served most recently as Executive Vice President, Corporate Development & General Counsel at Opiant Pharmaceuticals, which was acquired by Indivior PLC.
  • We welcome Brian to the team and look forward to working with him as we embark on the next chapter of our journey," said Renée Aguiar-Lucander, CEO Calliditas.

Calliditas announces additions to the management team

Retrieved on: 
Friday, December 1, 2023

STOCKHOLM, Dec. 1, 2023 /PRNewswire/ -- Calliditas Therapeutics AB (Nasdaq: CALT) (Nasdaq Stockholm: CALTX) ('Calliditas') today announced that the company has added a new member to its management team, Head of Technical Operations Lars Stubberud.

Key Points: 
  • STOCKHOLM, Dec. 1, 2023 /PRNewswire/ -- Calliditas Therapeutics AB (Nasdaq: CALT) (Nasdaq Stockholm: CALTX) ('Calliditas') today announced that the company has added a new member to its management team, Head of Technical Operations Lars Stubberud.
  • Brian Gorman is an accomplished legal and business executive with more than 20 years of experience advising corporate boards and executive management teams of life science companies.
  • He joins Calliditas after having served most recently as Executive Vice President, Corporate Development & General Counsel at Opiant Pharmaceuticals, which was acquired by Indivior PLC.
  • We welcome Brian to the team and look forward to working with him as we embark on the next chapter of our journey," said Renée Aguiar-Lucander, CEO Calliditas.

Opioid Use Disorder Market Insights, Epidemiology and Forecasts, 2019-2032: Focus on United States, Germany, Spain, Italy, France, United Kingdom, and Japan - ResearchAndMarkets.com

Retrieved on: 
Friday, October 27, 2023

The "Opioid Use Disorder (OUD)" report delivers an in-depth understanding of the Opioid Use Disorder (OUD), historical and forecasted epidemiology as well as the Opioid Use Disorder (OUD) market trends in the United States, EU4 (Germany, Spain, Italy, and France) and the United Kingdom, and Japan.

Key Points: 
  • The "Opioid Use Disorder (OUD)" report delivers an in-depth understanding of the Opioid Use Disorder (OUD), historical and forecasted epidemiology as well as the Opioid Use Disorder (OUD) market trends in the United States, EU4 (Germany, Spain, Italy, and France) and the United Kingdom, and Japan.
  • The Opioid Use Disorder (OUD) market report provides current treatment practices, emerging drugs, market share of individual therapies, and current and forecasted 7MM Opioid Use Disorder (OUD) market size from 2019 to 2032.
  • Opioid Use Disorder (OUD) Treatment FDA-approved drugs such as Buprenorphine, methadone, and naltrexone have proven effective in treating Opioid Use Disorder, decreasing overdose rates.
  • Which type of Opioid Use Disorder (OUD), as per severity, is the largest contributor to the Opioid Use Disorder (OUD) patient pool?

Indivior Enters an Exclusive Licensing Agreement with Alar Pharmaceuticals

Retrieved on: 
Wednesday, October 11, 2023

RICHMOND, Va., Oct. 11, 2023 /PRNewswire/ -- Indivior PLC (LSE/Nasdaq: INDV), a leading addiction treatment company, today announced that it has gained exclusive global rights to develop, manufacture, and commercialize Alar Pharmaceuticals Inc.'s ("Alar") portfolio of long-acting injectable formulations that release a prodrug1 of buprenorphine at varying durations, including its lead long-acting injectable ("LAI") candidate, ALA-1000.

Key Points: 
  • Under the agreement with Alar, Indivior will pay $10 million to secure exclusive global rights (except in China, Hong Kong, Taiwan and Macau) to develop, manufacture and commercialize ALA-1000 and Alar's future buprenorphine-based LAI product candidates.
  • The $10 million payment is in addition to an initial $5 million option payment made by Indivior to Alar in Q1.
  • Alar is entitled to potential milestone payments if various developmental, regulatory, and commercial goals are achieved.
  • Alar has been granted composition of matter and formulation patents for ALA-1000 covering sustained-release buprenorphine formulations with expiry in 2037 and 2039.

Indivior Publishes Real World Data Showing SUBLOCADE® May Reduce Non-Fatal Overdoses Among Individuals with Opioid Use Disorder in Canada

Retrieved on: 
Tuesday, September 26, 2023

This study, conducted during the COVID-19 pandemic in Canada, also showed improvements in additional parameters suggestive of clinical benefit.

Key Points: 
  • This study, conducted during the COVID-19 pandemic in Canada, also showed improvements in additional parameters suggestive of clinical benefit.
  • The percentage of individuals with urinary drug screen (UDS)-detected fentanyl use within the first month of treatment was 23% with SUBLOCADE; 22% with sublingual buprenorphine/naloxone, and 66% with methadone.
  • During the six months following the initiation of treatment, UDS-detected fentanyl use decreased to 13% with SUBLOCADE, 10% with sublingual buprenorphine/naloxone, and 51% with methadone.
  • "This study shows the potential positive impact of using SUBLOCADE in OUD treatment to help reduce non-fatal opioid overdoses in Canada, including from fentanyl use," said Christian Heidbreder, PhD, Chief Scientific Officer, Indivior.

Chasing Breakthrough Innovation in a Time of Uncertainty With Insights from McKinsey & Company

Retrieved on: 
Tuesday, September 19, 2023

TRENTON, N.J., Sept. 19, 2023 /PRNewswire/ -- BioNJ has released the agenda and speaker roster for its Eleventh Annual C-Suite Summit, taking place Friday, October 6, 2023, at the Bridgewater Marriott. The C-Suite Summit brings together life sciences executives representing a wide breadth of companies from early to late stage, public and private and revenue and pre-revenue to discuss the topics impacting C-Suite decision-making in bringing new innovative treatments to market.

Key Points: 
  • Friday, October 6, 2023 • 7:30 a.m.-4:00 p.m. Bridgewater Marriott, 700 Commons Way, Bridgewater
    TRENTON, N.J., Sept. 19, 2023 /PRNewswire/ -- BioNJ has released the agenda and speaker roster for its Eleventh Annual C-Suite Summit, taking place Friday, October 6, 2023, at the Bridgewater Marriott.
  • The C-Suite Summit brings together life sciences executives representing a wide breadth of companies from early to late stage, public and private and revenue and pre-revenue to discuss the topics impacting C-Suite decision-making in bringing new innovative treatments to market.
  • "As the policy environment churns and investment in biopharma fluctuates, questions are being raised about the future of innovation for our industry," said BioNJ President and CEO, Debbie Hart.
  • "The C-Suite Summit allows stakeholders to come together for an open conversation on where the greatest opportunities lie and how to best prepare for and shape the next paradigm in life sciences and medical discovery."

Click Therapeutics Announces Collaboration with Indivior to Develop and Commercialize Novel Prescription Digital Therapeutics in Substance Use Disorders

Retrieved on: 
Thursday, September 7, 2023

Click Therapeutics today announced the execution of a new collaboration agreement with Indivior for the development and commercialization of prescription digital therapeutics to treat substance use disorders, beginning with Opioid Use Disorder (OUD).

Key Points: 
  • Click Therapeutics today announced the execution of a new collaboration agreement with Indivior for the development and commercialization of prescription digital therapeutics to treat substance use disorders, beginning with Opioid Use Disorder (OUD).
  • Through a novel mobile application, CT-102, the collaboration aims to help close major gaps in OUD treatment, such as access to high-quality, personalized psychosocial treatment.
  • This collaboration will build on Indivior’s expertise in the commercialization of innovative treatments for substance use disorders and Click Therapeutics’ substantial real-world experience engaging patients seeking help with addiction.
  • This is the fourth major co-development and commercialization collaboration to be announced that is based on Click Therapeutics’ clinically validated platform.